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A process is a function of time; in immunometabolism, this is reflected by the stepwise
adaptation of metabolism to sustain the bio-energetic demand of an immune-response in
its various states and shades.This perspective article starts by presenting an early attempt
to investigate the physiology of inflammation, in order to illustrate one of the basic concepts
of immunometabolism, wherein an adapted metabolism of infiltrating immune cells affects
tissue function and inflammation. We then focus on the process of macrophage activation
and aim to delineate the factor time within the current molecular context of metabolic-
rewiring important for adapting primary carbohydrate metabolism. In the last section, we
will provide information on how the pentose phosphate pathway may be of importance
to provide both nucleotide precursors and redox-equivalents, and speculate how carbon-
scrambling events in the non-oxidative pentose phosphate pathway might be regulated
within cells by demand. We conclude that the adapted metabolism of inflammation is spe-
cific in respect to the effector-function and appears as a well-orchestrated event, dynamic
by nature, and based on a functional interplay of signaling- and metabolic-pathways.
Keywords: immunometabolism, inflammation, macrophage activation, metabolic reprograming, primary carbohy-
drate metabolism, pentose phosphate pathway, sedoheptulose kinase, time and demand
CONCEPTS OF IMMUNOMETABOLISM
The first concepts of immunometabolism date back to the pre-
genomic age of biomedical research. As early as 1912, Levene and
Meyer used dog blood-derived leukocytes to directly demonstrate
that hexoses are converted into two molecules, each containing a
chain of three carbons (1). They also provided further evidence
that hexoses are the source of lactate and assumed that this process
accounts for “synthethic purposes by the leukocytes.” This period
is widely recognized as the onset of modern biochemistry and
furthermore of immunometabolism.
Immunometabolism is also tightly linked to research on can-
cer metabolism, especially with regard to the pioneering work
of Otto Warburg, wherein he further developed the concept of
cellular physiology (2). It was revealed that exudate leukocytes
have high aerobic glycolysis, while respiration was very low and
it was concluded then that white blood cells must have a can-
cer metabolism (3, 4). However, they differentiated immune cell-
and cancer metabolism in that cancer cells use aerobic glycoly-
sis to live, while aerobic glycolysis in white blood cells is a sign
of aging or dying off. With this background, Walter Kempner
and Ernst Peschel, both from the Bergmann’sche Institut at the
Charite in Berlin, published their work with the German title:
“Stoffwechsel der Entzündung” (Metabolism of Inflammation)
(5). In 1930, they formulated two fundamental questions: what
are the specific reactions of inflammation? Which processes lead
to cell migration and subsequently to tissue swelling or necro-
sis? They presumed that an adapted cellular metabolism of white
blood cells may play a major role in these processes. They tested
their hypothesis in a human in vivo model of sterile-inflammation
and provided fundamental new insights, which are still of rele-
vance for today’s concepts of immunometabolism. Kempner and
Peschel used the beetle-juice (cantharidin)-induced skin blister
model and metabolically defined the inflamed human tissue in
order to examine the physiology of inflammation. They observed
a disrupted equilibrium of oxygen, CO2, sugar, lactate, and bicar-
bonate as a result of inflammation and concluded that this was
induced by the metabolism found in infiltrating immune cells.
They expected this to happen as a function of time. They demon-
strated a drop in glucose over a period of 6–90 h and pulsed
oral glucose administrations indicating that glucose replenish-
ment from healthy tissue was also gradually declining. Within the
inflamed area (the blister) also oxygen concentration declined.
This was again attributed to high cellular respiration of infil-
trated cells and a reduced gas-exchange with the healthy tissue.
In addition to that, they measured a time-dependent increase in
lactate and a decrease in the bicarbonate levels, which together
could explain the decrease in pH of inflamed tissue, previously
observed by Schade (6). Kempner and Peschel identified metabolic
changes in inflamed tissue as a function of time, which is actively
established by infiltrating “injured” immune cells with an adapted
cellular metabolism (5). Thereby, they delineated a complex inter-
play between cellular metabolism and the physiology of inflam-
mation. In 2011, the cantharidin-induced skin blister was re-
evaluated and recommended as an excellent human in vivo model
to study inflammation (7). This report also reveals that the infil-
trating cells in this model are mainly neutrophils and monocytes/
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macrophages; these cells were probably also the cause for the
observation by Kempner and Peschel.
Since then, a new school of immunobiology has started to
reveal the molecular mechanism behind the observed metabolic-
adaptation in various immune cells and models of immunology.
As an example, the action of the pentose phosphate pathway (PPP)
and the power of redox-biology, including superoxide production,
were identified as essential in forming the respiratory-burst of
phagocytes (8, 9). Also amino acid and lipid metabolism, as well
as their adaptations, were characterized as fundamental to prop-
erly fuel the function of an immune response (10, 11). In recent
years, however, new concepts in immunometabolism have evolved
and further mechanistic-details have surfaced that enable us to
better understand how these metabolic-adaptions are reached and
regulated.
TIME RESOLVED METABOLIC-ADAPTATIONS DURING
MACROPHAGE ACTIVATION
Macrophages are important immune cells, which regulate tissue
homeostasis by sensing and interpreting cell injury and infec-
tion, the classic triggers of an inflammatory response (12). Today,
macrophages are classified according to the activation stimuli into
at least two polarization states, the classic M1 (representing a pro-
inflammatory phenotype) and the alternative M2 macrophage
(representing an anti-inflammatory or homeostasis inducing phe-
notype), in order to discriminate between the effector phenotypes
resulting from the distinct activation signals (13). However, in vivo
macrophages rather appear to blend into various “shades of acti-
vation,” while retaining some of their plasticity (14–18). Further-
more, macrophage populations and phenotypes can dramatically
change over time, as exemplified by the finding that the inflamma-
tory response is a spatially and temporally coordinated process.
Recently, the polarization process of macrophages has been fur-
ther associated with the reprograming of cellular metabolism
(19–25). Information processing by signal-transduction path-
ways starts shortly after activation and is temporally coordinated,
reflected by the phosphorylation and de-phosphorylation of sig-
nal transducers and effector molecules. The question arises how
the reprograming of primary carbohydrate metabolism is timed
in the process of macrophage activation. We would like to present
more detailed and more importantly time-resolved information
on key events, which appear to establish a pro-inflammatory M1-
like metabolic-phenotype induced by lipopolysaccharide (LPS,
Figure 1).
After only 20 min of in vitro LPS-stimulation, simultaneously
with prime signaling events, the glucose uptake of cells approxi-
mately doubles (26). At the same time, the extracellular acidifica-
tion rate (ECAR), an indirect measure of aerobic glycolysis, also
increases until reaching a certain plateau-state, to then adapt, and
further increase (21). This response indicates that LPS leads to a
rapid induction of glycolytic flux, which is modulated and ampli-
fied in multiple steps (Figure 1). The extension phase of ECAR is
accompanied by a slow and marginal decrease in the oxygen con-
sumption rate (OCR). The molecular mechanisms leading to these
immediate early metabolic events, however, are not known and
acidification may also result from sources other than the formation
of lactic acid.
However, 1 h after LPS stimulation, the mRNA of the glucose
transporter (GLUT1) is induced and the uptake of glucose further
increases (26). After uptake of glucose, it becomes phosphory-
lated by hexokinases (HK) to glucose 6-phosphate (G6P), which
can then be diverted into various catabolic and anabolic path-
ways. Non-stationary metabolic flux analysis, tracking the fate of
intracellular glucose during macrophage activation, reveals that
already 1 h after LPS-exposure a considerable amount of glu-
cose is used by both, glycolysis and the PPP (21). In rat-Kupffer
cells, which are specialized liver macrophages, as well as murine
dendritic cells, HK-II was shown to associate with mitochondria
within an hour after LPS stimulation (27, 28). A similar mech-
anism is observed in cancer cells, where mitochondrial matrix
derived ATP is channeled to HK-II and thereby augmenting the
glycolytic flux (29). Recently, the sedoheptulose kinase (Shpk,
formerly known as CARKL) was characterized as a unique hep-
tose kinase, phosphorylating sedoheptulose (a ketoheptose) to
sedoheptulose 7-phosphate (S7P), which can then act as a reac-
tion partner of glyceraldehyde 3-phosphate (G3P) in the non-
oxidative PPP (21, 30–32). In macrophages, the mRNA of Shpk
is rapidly down-regulated by LPS but not by interleukin (IL)-4
stimulation (21). Regulation of Shpk will be further discussed
in the next section. Also, approximately after 1 h, LPS specifi-
cally induces pyruvate kinase M2 (PKM2) protein expression and
phosphorylation, which becomes further augmented in the late
phase of macrophage activation (23). Phosphorylation of PKM2
favors dimeric configuration and PKM2 translocation into the
nucleus, where it acts together with hypoxia-inducible factor 1-
alpha (HIF1α) as a transcriptional inducer of interleukin 1-beta
(IL-1β) and more importantly of glycolytic genes like PFK, con-
stituting an amplification loop in the intermediate and late phase
of macrophage activation (23, 33). Within 2–4 h after activation
by LPS, an isoform switchs from the liver-type 6-phosphofructo-
2-kinase (PFKFB1 aka PFK2) to the ubiquitous and more active
PFKFB3 occurs (34). This is also observed when LPS is used in
combination with interferon gamma (IFNγ) to induce a pro-
inflammatory macrophage activation (20). PFKFB3 produces aug-
mented levels of fructose 2, 6-bisphosphate (F2,6bP), which then
functions as an allosteric activator of 6-phosphofructo-1-kinase
(PFK1) to further sustain the pro-glycolytic program (Figure 1).
Interestingly in yeast, PFK1 derived F1,6bP allosterically activates
PKM2, indicating the presence of metabolic feedback loops (35).
Approximately 4–6 h after macrophage activation, the export
of glycolytic lactate appears to become mandatory for the acti-
vation process as indicated by the increased expression of mono-
carboxylate transporter 4 (MCT4) (36). Knockdown of MCT4
results in enhanced intracellular lactate accumulation, a decreased
expression of LPS-induced glycolytic enzymes and an attenu-
ated secretion of tumor necrosis factor-alpha (TNFα) and IL-6.
Accumulating intracellular lactate might decrease glycolytic activ-
ity by inhibiting PFK1, an enzyme which may reach maximal
activity in the later phase, as indicated by peaking F2,6bP con-
centrations and PFKFB3 mRNA levels at 6–12 h (34, 37). Also,
approximately 4 h after initiation of macrophage polarization
by LPS, the tricarboxylic acid (TCA) cycle changes its opera-
tional mode from a catabolic pathway to a partly anabolic system
(21, 22). The TCA-cycle metabolite succinate accumulates in a
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FIGURE 1 |Time-resolved metabolic reprograming during
pro-inflammatory macrophage polarization. This model illustrates the
activation of a macrophage as a function of time and is based on the literature
discussed in the main text. LPS-induced activation can be grouped into an
initiation-, an early metabolic-reprograming,- and an amplification-phase. The
initiation phase of the metabolic response is characterized by an increase in
glucose consumption and in the extracellular acidification rate (ECAR). The
early metabolic reprograming phase depicts the increase and rerouting of
carbon flux through glycolysis and the PPP, events which also regulate the
cellular redox-state. In this setting, the mitochondrial association of
hexokinase-II (HKII) appears to provide sufficient levels of glucose
6-phosphate (G6P), while the downregulation of sedoheptulose kinase (Shpk,
previously known as CARKL) appears to be necessary to maintain appropriate
carbon flux at the interface of glycolysis and the PPP. During the amplification
phase, this pro-glycolytic metabolic-phenotype is further strengthened. A
switch toward the more active 6-phosphofructo-2-kinase (PFK2) enzyme
PFKFB3 produces higher levels of fructose 2-bisphosphate [F2,6bP], thus
allosterically activating PFK1 and enhancing glycolytic flux. Dimers of the
pyruvate kinase M2 (PKM2), as well as accumulating succinate further
augment metabolic reprograming by supporting HIF-1α dependent
transcriptional induction of glycolytic genes. In the amplification phase, also
the export of intracellular glycolysis-derived lactate through monocarboxylate
transporter 4 (MCT4) becomes obligatory, which may otherwise inhibit PFK1.
These initial events lead to more prominent metabolic changes observed 24 h
after macrophages have encountered the pro-inflammatory stimuli. However,
further time-resolved data is required to refine these processes and our
current perspective, how cellular metabolism of macrophages adapts during
activation.
macrophage cell line and bone marrow derived macrophages
(BMDMs) (21, 22). Succinate, derived by glutamine-dependent
anerplerosis and gamma-aminobutyric acid (GABA)-shunt, was
shown to inhibit the prolyl hydroxylase-dependent degradation of
HIF1α and to enhance IL-1β production (22). Increased succinate
levels may also increase succinylation of metabolic enzymes such
as glyceraldehyde 3-phosphate dehydrogenase (GAPDH), transal-
dolase (TALDO), and lactate dehydrogenase (LDH) A-chain, pos-
sibly further shaping late phase metabolic adaptations (22, 38).
Succinate dependent HIF1α stabilization as well as increased suc-
cinylation are both suppressed by the inhibition of glycolysis, indi-
cating that these processes are dependent on increased glycolytic
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flux (22, 23). Approximately 24 h after LPS-stimulation, metabolic
reprograming is firmly established: glycolytic gene expression and
metabolites are increased, as well as lactate and ECAR (22, 23).
The TCA-cycle supports increased fatty acid synthesis as well as
the formation of cycle intermediates (succinate, malate, fumarate),
while OCR is reduced, indicating a significant decline in oxidative
metabolism (22, 23).
To briefly summarize the overall consequences of the discussed
adaptations: LPS stimulated macrophages increase aerobic gly-
colysis and PPP activity, reduce mitochondrial respiration, and
reconfigure the TCA-cycle. In order to replenish NAD+ for gly-
colysis, lactate production and secretion are enhanced, leading
to acidification of the environment. Such a pro-inflammatory
metabolism is important for the generation of redox-equivalents
as well as precursor molecules such as amino acids, lipids, and
nucleotides, sustaining a burst in pro-inflammatory mediator pro-
duction (39, 40). In reference to protein-signal-transduction lead-
ing to the observed metabolic adaptions, nuclear factor kappa-B
(NFκB) and HIF1α are two well-characterized transcription fac-
tors, which increase the expression of glycolytic genes (41, 42). In
contrast to an pro-inflammatory activation of macrophages, alter-
native activation (i.e., by IL-4) is associated with mitochondrial
biogenesis as well as increased fatty acid oxidation and oxida-
tive phosphorylation, primarily driven by lysosomal lipolysis of
endocytosed lipoprotein particles (24, 43). In general, the M2
metabolic program mainly relies on STAT6, PPARγ, and its co-
activator PGC1β to promote oxidative metabolism. The manifold
metabolic changes during macrophage activation as well as their
regulatory mechanisms have been recently discussed in detail in
some excellent reviews (44–46).
THE PPP SUSTAINS THE METABOLIC DEMAND OF
MACROPHAGES DURING POLARIZATION
The PPP represents a prime example on how increased carbon-
flux can contribute to mount the specific effector functions of
LPS-activated macrophages by complementing their appropri-
ate demands through supplying both redox-power and ribose
moieties either at the same time or independently from each
other. The PPP is divided into the oxidative (oxPPP) and non-
oxidative branch (non-oxPPP). Briefly, the oxPPP, with glucose
6-phosphate dehydrogenase (G6PD) as its rate-limiting enzyme,
is highly active in macrophages (21, 47), decarboxylates G6P, and
forms ribose 5-phosphate (R5P) through three irreversible reac-
tions, while simultaneously reducing two molecules of NADP+ to
NADPH and liberating one molecule of CO2. The non-ox PPP
consists of reversible reactions, which can either recycle R5P to
glycolytic intermediates or use the latter to generate pentose phos-
phates (C5P) through reverse flux. The general aspects of PPP
architecture and function have been reviewed elsewhere in great
detail (48–50).
Oxidative PPP derived NADPH serves as a cofactor for
NADPH-oxidase dependent reactive oxygen species (ROS) pro-
duction, while also reducing oxidized redox-couples to simulta-
neously sustain an anti-oxidant response (i.e., glutathione and
thioredoxin systems), thereby partly controlling the redox bal-
ance during macrophage activation (51, 52). Also, the function of
many redox-sensitive signaling proteins, which are associated with
the process of activation, are potentially dependent on increased
flux through the oxPPP (53–59). Furthermore, NADPH is also
critical for reductive biosynthesis serving activation associated
membrane expansion and the production of lipid mediators such
as prostaglandins. Remarkably, it was reported that NADPH lev-
els undergo periodic oscillations in macrophages and neutrophils,
which are tightly linked to superoxide oscillations and adapt, upon
LPS stimulations to a higher frequency (60–63). These oscilla-
tions may depend on periodic glucose influx and PPP activity, and
appear to encode information in their amplitude and frequency
(64, 65). Severe G6PD deficient leukocytes have been associated
with impairments in their oxidative burst, their bactericidal activ-
ity (66–68), their resistance to oxidative stress (69), as well as
modified cytokine responses (70–72). Overexpression of G6PD
in a macrophage cell line enhanced the activation of NFκB and
p38-MAPK signaling pathways and potentiated the expression of
pro-inflammatory cytokines as well as ROS production (73). In
contrast to IL-1β, the production of TNFα and IL-6 does not
appear to be directly dependent on aerobic glycolysis, as recently
suggested by the activation of PKM2 and 2-deoxyglucose (2-DG)
treatment, respectively (22, 23). Notably, 2-DG is a glycolytic
inhibitor downstream from hexokinase and can therefore become
phosphorylated to 2-deoxyglucose 6-phosphate, which is partly
metabolized by the oxPPP in red blood cells (74). Whether this also
occurs in macrophages or not remains to be investigated. Inhibi-
tion of G6PD or LDH, however, was shown to decrease TNFα and
IL-6 levels, implicating that these cytokines are rather regulated
by redox-state than simply by the increased glycolytic-flux (21).
Apart from redox-power, the macrophage activation process also
demands a large amount of pentose phosphates probably to sustain
de novo nucleotide synthesis for their characteristic transcriptional
response. In contrast to M2, M1 macrophages drastically change
their transcriptional profile (40). Isotope distribution analysis of
a non-stationary metabolic flux experiment with asymmetrically
labeled glucose after 1 h of LPS-induced macrophage activation
indicated that both ox- and non-oxPPP flux rates increase, while
most of the pentose phosphates (C5) are derived from the non-ox
branch (21).
The non-oxPPP relies on transketolase (TK) and TALDO cat-
alyzed reversible transfer of keto-groups to various aldose accep-
tors. TK uses thiamine pyrophosphate as cofactor to transfer two
carbon (C2)-units, while TALDO can transfer C3-units by forming
Schiff base intermediates (75, 76). Thereby, this pathway inter-
converts carbohydrate-phosphates of different chain length (C3P
to C7P), without the need of energy in form of ATP (carbon
scrambling, Figure 2A). The regulation of non-oxPPP is com-
plex due to its reversible nature and still not fully understood.
The flux-rate and its direction are generally thought to depend
on thermodynamics, which impose a major constraint on the
structure of metabolic pathways (77). However, the recent identifi-
cation of Shpk indicates additional regulatory mechanism, which
was previously not considered (Figure 2B) (78). In contrast to
TK or TALDO, Shpk is reported to be regulated differently dur-
ing LPS- and IL-4 induced polarization (21). LPS stimulation
leads to a rapid down-regulation of Shpk mRNA in the early
phase of macrophage activation in mice and humans likewise and
in vitro as well as in vivo. In contrast to LPS, IL-4 stimulation
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FIGURE 2 |The function and regulation of the non-oxidative PPP.
(A) represents a simplified model, which illustrates how transketolase (TK)
and transaldolase (TALDO) may interconvert carbohydrate-phosphates of
three to seven carbon-atoms in length (C3P to C7P) without the need of
energy (carbon-scrambling) to account for the cellular demand, which in part
defines cell function (indicated by the symbol f (x )). In (B), we theoretically
evaluate the regulatory effect of Shpk-derived sedoheptulose 7-phosphate
([C7P]Shpk) on non-oxPPP flux in the presence of TK and TALDO. Flux through
the non-oxPPP, by its reversible reactions, is dependent on the stoichiometry
of the reactants (indicated by green arrowheads). In contrast to TK- and
TALDO-derived S7P, the phosphorylation of free sedoheptulose to S7P by
Shpk requires energy in form of ATP. Assuming a constant contribution by
Shpk, this additional source of S7P may therefore act as a thermodynamic
buffer, which can be actively regulated to induce a non-equilibrium. In theory,
perturbation of Shpk can either increase the resistance (increased [C7P]Shpk) or
lower it (decreased [C7P]Shpk) to support shunting through the non-oxPPP.
However, in the presence of TK or TALDO, an increased [C7P]Shpk will promote
the incorporation of glycolytic-G3P into the PPP. This model further illustrates
that non-oxPPP flux-direction is also dependent on the demand of respective
molecules (indicated by red arrowheads).
maintains or even slightly increases Shpk levels (21). Counterbal-
ancing LPS-induced down-regulation of Shpk by overexpression
in a macrophage cell line resulted in an accumulation of pen-
tose phosphates and an imbalance of the cellular redox system,
as indicated by the accumulation of oxidized redox couples as
well as blunted LPS-induced intracellular superoxide produc-
tion (21). In theory, Shpk, by the formation of rate-limiting S7P,
should increase the shunting of glycolysis-derived G3P into the
non-oxPPP (78) and regulate oxPPP activity through the for-
mation or recycling of pentose phosphates (79). So far, we have
no confirmed mode-of-action, how Shpk activity actually regu-
lates carbon-flux through the non-oxPPP, and no information on
its activity and local distribution during macrophage activation.
Therefore, we can only speculate on the consequences of Shpk
regulation for the process of metabolic-adaptation (Figure 2B).
Shpk-derived S7P may act as a thermodynamic buffer to sup-
port a stable non-equilibrium, which drives (low S7P) or inhibits
(high S7P) carbon-flux through the non-oxPPP. However, flux-
direction seems to be determined by demand and by the presence
of TK and TALDO (Figure 2B). In addition to that, high S7P lev-
els can directly modulate glycolytic flux through the inhibition of
hexose phosphate isomerase, as well as by competitively inhibit-
ing fructose 6-phosphate (F6P) phosphorylation by PFK (80, 81).
Therefore, the consequences of Shpk regulation appear as strictly
context dependent, which is defined by the demand of metabo-
lites (i.e., C5P) and the presence or absence of other enzymes.
We know that Shpk only partially colocalizes with G6PD in the
cytoplasm of cells, which points out that there are instances where
the ox- and the non-oxPPP are coupled to and uncoupled from
each other (21). Information on the function of TK and TALDO
in the process of macrophage activation is rare; however, both
enzymes were tightly linked to oxidative stress-defense in other cell
types (82–84). Notably,yeast seems to lack a Shpk homolog but uti-
lizes a specific sedoheptulose–bisphosphatase [dephosphorylates
sedoheptulose 1,7-bisphosphate (S1,7bP) to S7P] for riboneoge-
nesis when the demand for nucleotide precursors is high (85).
S1,7bP was previously reported to also exists in rat liver tissue
(86, 87); however, there appear to be some major differences in the
architecture of heptose metabolism (heptolysis) between fungi and
vertebrates (78, 85).
In summary, these findings indicate that during macrophage
activation the cellular demands are covered by a precisely coordi-
nated interplay of many pathways to sustain such profound polar-
ization events. The PPP appears as a versatile hub to reroute carbon
moieties within the network of primary carbohydrate metabolism
while independently controlling cellular redox-states.
CONCLUSION
This collection of findings may support our perspective that time
and demands are critical to understand the molecular events
important to mount an immune response. Immunometabolism
demonstrates its consequences for physiology at various levels
including cells, tissues, organisms, and entire populations, as we
currently experience with diseases like cancer, cardiovascular dis-
eases, obesity, and diabetes to name but a few. Already, Kempner
and Peschel considered diabetic patients in their investigations
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and noted a sustained glucose supply together with a prolonged
inflammatory response compared to non-diabetics. Since then,
many excellent studies further delineated the complex inter-
play of metabolism, the immune system and tissue function,
and malfunction. At the molecular level, macrophages adapt
their metabolism very early in the polarization process, which
then become amplified over time. This highlights that we need
to strongly consider the process leading to activation and not
only the phenotypic “endpoints.” A macrophage located within
a complex tissue microenvironment may go through multi-
ple, subsequently occurring, activation events, which then may
amplify or antagonize each other. It will be interesting to test
in vivo if, and importantly how, subsequent or parallel cross-
presentation of multiple activation-stimuli (i.e., pro- and anti-
inflammatory signals such as LPS, IFNγ, TNFα, IL-6, IL-4, or
IL-10) may skew and define the process of metabolic reprograming
in macrophages.
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